Biocon Biologics signs settlement, license agreement to commercialize biosimilar Aflibercept worldwide

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-12-14 11:00 GMT | Update On 2025-12-14 11:01 GMT

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced a new settlement and license agreement with Regeneron and Bayer for biosimilar Aflibercept (40mg/ml) in Europe and the rest of the world, which follows an earlier settlement covering the United States and Canada.

This agreement clears the way for Biocon Biologics to commercialize Yesafili, a biosimilar Aflibercept (40mg/ml), in all countries worldwide.

YESAFILI is a vascular endothelial growth factor (VEGF) inhibitor used to treat multiple ophthalmology conditions.

It is intended for the treatment of neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).

Biocon Biologics, Regeneron and Bayer executed the agreement to dismiss all pending litigation. This agreement enables the Company to launch YESAFILI in the United Kingdom in January 2026 and in the rest of the settled countries in March 2026 or earlier in certain circumstances. The other terms of the settlement are confidential.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said, “This settlement paves the way for Biocon Biologics to make available our biosimilar Aflibercept globally. This milestone expands our presence in the ophthalmology therapeutic area as we work closely with healthcare systems to increase access to patients everywhere.”

The European Commission (EC) and the Medicines & Healthcare products Regulatory Agency (MHRA) have previously approved YESAFILI.

Biocon Biologics secured a market entry for its biosimilar Aflibercept for the U.S. in April 2025, for second half of calendar year 2026 or earlier in certain circumstances. YESAFILI was launched in Canada earlier this year and the market entry was secured for Canada in March 2024.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Biocon Biologics signs settlement, license agreement to commercialize biosimilar Aflibercept worldwide

Similar News

JnJ bags USFDA nod for Akeega plus prednisone for BRCA2 mutated metastatic castration sensitive prostate cancer

Bayer-Regeneron Aflibercept 8 mg recommended for EU approval for third retinal indication

Counterfeit Drug Racket Using Lupin Brand Busted in Puducherry, FIR Filed

Trainee Pharmacist Allegedly Sexually Harassed at Parganas Hospital, 1 Held

Centre Mandates QR Codes for Top Medicines, APIs: Minister

Merck receives positive EU CHMP opinion for expanded use of Winrevair in adults with Pulmonary Arterial Hypertension

Sanofi gets approval for 2 rare hematologic diseases medicines in China